SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

30 Jan 2024 Evaluate
The sales surged to Rs. 5200.15 millions, up 34.54% for the December 2023 quarter as against Rs. 3865.14 millions during the corresponding quarter previous year.A radical decline of -79.72% was reported in the net profit of the company for the quarter ended December 2023 to Rs. 25.42  millions from Rs. 125.36 millions.The company reported a degrowth in operating Profit to 743.41 millions from 753.57 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 5200.15 3865.14 34.54 15356.26 12909.39 18.95 18544.96 19790.03 -6.29
Other Income 86.86 297.52 -70.81 426.72 576.88 -26.03 840.66 1234.85 -31.92
PBIDT 743.41 753.57 -1.35 2071.57 367.30 464.00 1825.43 2001.15 -8.78
Interest 444.67 351.04 26.67 1211.62 957.81 26.50 1386.82 742.41 86.80
PBDT 245.83 402.53 -38.93 807.04 -590.51 -236.67 288.61 1258.74 -77.07
Depreciation 210.63 222.62 -5.39 638.61 709.09 -9.94 936.21 1043.66 -10.30
PBT 35.20 179.91 -80.43 168.43 -1299.60 -112.96 -647.60 215.08 -401.10
TAX 9.78 54.55 -82.07 50.16 -722.45 -106.94 -694.42 -1586.80 -56.24
Deferred Tax 3.03 128.08 -97.63 18.76 -454.11 -104.13 -195.99 -2.09 9277.51
PAT 25.42 125.36 -79.72 118.27 -577.15 -120.49 46.82 1801.88 -97.40
Equity 918.86 903.33 1.72 918.86 903.33 1.72 903.03 897.90 0.57
PBIDTM(%) 14.30 19.50 -26.67 13.49 2.85 374.14 9.84 10.11 -2.66

Strides Pharma Scien Share Price

1019.00 -11.60 (-1.13%)
24-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1941.00
Dr. Reddys Labs. 1152.60
Cipla 1410.90
Lupin 2369.45
Zydus Lifesciences 1108.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: